203 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
Reg. FD
Investor Presentation
Earnings Release
ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK
Announces Preliminary Financial And Operational Results For The Second Quarter Ended June 30, 2025
Shareholder votes
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities